NASDAQ: AMPH · Specialty & Generic Drug Manufacturers
Amphastar Pharmaceuticals (AMPH) fair value and price range
As of 26 Sep 2026, Faircurve's model values Amphastar Pharmaceuticals (AMPH) at $26.29 a share. The stock last closed at $25.43, which puts the model's fair value 3.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Amphastar Pharmaceuticals, Inc.
Faircurve Insights · 26 Sep 2026
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise.
Faircurve's model found a fair value of $26.29 a share on 26 Sep 2026, which is the midpoint of 2,000 simulations. The fair value moved +10.6% since the previous run on 19 Sep 2026, which gave $23.77. The calibrated range over 63 trading days is $22.06 to $32.06, built from the fair value, and held the price 60% of the time at this horizon in 4,327 past valuations. The model grades the evidence behind this valuation as low.
The business quality is scored against Supernus Pharmaceuticals, Inc. (SUPN), Amneal Pharmaceuticals, Inc. (AMRX), and Lantheus Holdings, Inc. (LNTH). The stock's moves around its last eight earnings reports ranged from +14.4% to -27.7%, with a median size of 9.8%.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give AMPH?
The calibrated range for AMPH over 63 trading days is $22.06 to $32.06. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $15.22 to $41.18. In 50% of the simulations the fair value came out above the price the model ran on.
How does AMPH compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Amphastar Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PCRX Pacira BioSciences, Inc. | $25.21 | $25.32 | +0.4% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $37.24 | $34.73 | -6.7% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $72.18 | $85.27 | +18.1% | Low evidence grade |
| COLL Collegium Pharmaceutical, Inc. | $22.02 | $29.48 | +33.9% | Low evidence grade |
| SUPN Supernus Pharmaceuticals, Inc. | $42.38 | $42.72 | +0.8% | Fairly valued |
| INDV Indivior Pharmaceuticals Inc | $35.71 | $36.01 | +0.8% | Low evidence grade |
| AMRX Amneal Pharmaceuticals, Inc. | $20.30 | $18.51 | -8.8% | Fairly valued |
| LNTH Lantheus Holdings, Inc. | $99.96 | $100.31 | +0.4% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
When does AMPH report earnings, and how has the stock reacted?
Amphastar Pharmaceuticals's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
How AMPH moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 9.8%.
| Report date | Two session move |
|---|---|
| 6 Aug 2026 | +2.7% |
| 7 May 2026 | -20.5% |
| 26 Feb 2026 | -27.7% |
| 6 Nov 2025 | -5.1% |
| 7 Aug 2025 | +14.4% |
| 7 May 2025 | +0.4% |
| 27 Feb 2025 | -8.9% |
| 6 Nov 2024 | -10.6% |
Amphastar Pharmaceuticals at a glance
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise.
- Market value
- $1.2B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $775M
- Consensus revenue growth, next fiscal year
- +3.9%
- Analysts with estimates
- 3
- Beta to the US market
- 0.66
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Amphastar Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for AMPH was $23.77. As of 26 Sep 2026 it is $26.29, a change of +10.6%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Amphastar Pharmaceuticals's valuation
Is Amphastar Pharmaceuticals stock undervalued or overvalued?
Faircurve's model puts AMPH's fair value at $26.29 a share against a last close of $25.43, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is AMPH's fair value?
$26.29 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $15.22 to $41.18.
What price range does the model give AMPH?
$22.06 to $32.06 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Amphastar Pharmaceuticals report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has AMPH moved on past earnings reports?
Across its last 8 reports the median two session move was 9.8%, ignoring direction. The largest was -27.7% around the report of 26 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for AMPH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.